ESR1 and breast carcinoma: About 24–30% of BRCA1-associated breast cancers and 65–79% of BRCA2-associated breast cancers are estrogen receptor-positive.57 In women with triple-negative breast cancer, HRT can be considered for short-term use on an individual basis, particularly in those with good prognosis.